We can’t show the full text here under this license. Use the link below to read it at the source.
Long-term prognostic impact of glucagon-like peptide-1 receptor agonist before ST-segment elevation myocardial infarction in patients with type 2 diabetes: a nationwide cohort study
Long-term outlook after heart attack in type 2 diabetes patients using a diabetes drug before the event
AI simplified
Abstract
In a cohort of 1,421 patients with and type 2 diabetes, 36% of those treated with GLP-1RA died over 8.4 years compared to 52% in those not treated.
- GLP-1RA treatment before STEMI is associated with lower long-term mortality, with a hazard ratio of 0.60.
- Only 7% of the patients received GLP-1RA treatment prior to STEMI.
- Patients on GLP-1RA were generally younger and had more comorbidities compared to those not treated.
- No significant association was found between GLP-1RA and the occurrence of ischemic stroke, recurrent myocardial infarction, or hospitalization for heart failure.
AI simplified
Key numbers
0.60
Lower Long-term Mortality
Adjusted hazard ratio for all-cause mortality in GLP-1RA group vs. no GLP-1RA group.
36% vs. 52%
Mortality Rate Comparison
Mortality rates during 8.4 years follow-up for GLP-1RA vs. no GLP-1RA group.